Latest research on Pregabalin

Pregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica. It is considered to have a dependence liability if misused, and is classified as a Schedule V drug in the U.S. [Wikipedia]

Latest findings

Pregabalin, a follow-up compound of the G ABA agonist, Gabapentin, is being developed for the potential treatment of several central nervous system disorders and anxiety, including social anxiety disorder. [source, 2002]
Pregabalin was purchased from Taconic (Tokyo). [source]
Gabapentin (1 mg/mouse) and Pregabalin (250 μg/mouse) were intraperitoneally injected into relapsing-remitting EAE induced SJL/J mice. [source]
Pain medicines such as Gabapentin and/or Pregabalin, which reduced cfos expression in neurons of the somatosensory area or von Frey test values after pain-induction (data not shown), suppressed the development of EAE relapse (Figure 1E). [source]
SNS-Cre/TdT+ neurons were highly enriched for Cacna2d1 (α2δ1) and for Cacna2d2 (α2δ2), the pharmacological targets of Gabapentin and Pregabalin (Wang et al., 1999; Field et al., 2006; Patel et al., 2013); unexpectedly, Parv-Cre/TdT+ neurons were enriched for Cacna2d3 (α2δ3) (Figure 6B), which contributes to heat nociception via supraspinal expression (Neely et al., 2010). [source]
Pregabalin, Gabapentin, Paroxetine, Oseltamivir, ZANAMIVIR are only some examples of drugs in which Phase III trials remain unpublished several years after study completion. [source]